Arbutus Biopharma (ABUS) Financials: Revenue & Earnings
ABUS$4.28-0.04 -1.04%
$846.90M
Market Cap
5.46
P/E
5.78
Forward P/E
81
Score
Arbutus Biopharma (ABUS) Financials: Revenue & Earnings
ABUS price $4.28 -0.04 -1.04%
- Ticker
- ABUS
- Price
- $4.28
- Change
- -0.04 -1.04%
- Market cap ?
- $846.90M
- P/E ?
- 5.46
- Forward P/E ?
- 5.78
- Dividend yield ?
- 0.00%
- Beta ?
- 0.62
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 81
- Value
- 64
- Quality
- 79
- Growth
- 100
Stocklytics score rationale: value 64, quality 79, growth 100.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 1500000 | 10700000 | 5900000 | 6011000 | 6914000 | 10988000 | 39019000 | 18141000 | 6171000 | 14083000 |
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1…
Earnings and financials
Arbutus Biopharma Corp (ABUS) trades at $4.28, with a market cap of $846.90M and a trailing P/E of 5.46. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 1500000 | 10700000 | 5900000 | 6011000 | 6914000 | 10988000 | 39019000 | 18141000 | 6171000 | 14083000 |
Insights · Dividends · Forecast · Financials · Learn